All studies
AuthorisedTherapeutic use (Phase IV)Interventional

Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.

People who have had surgery to remove their thyroid gland need daily thyroid hormone tablets to replace what their body can no longer make. For those with advanced thyroid cancer who are also taking targeted cancer medicines called tyrosine kinase inhibitors (TKIs), keeping thyroid hormone levels stable can be tricky. Usually, doctors prescribe a single hormone called levothyroxine (LT4). This trial is testing whether adding a second thyroid hormone called liothyronine (LT3) helps keep thyroid-stimulating hormone (TSH) in a healthy, safe range more reliably. Participants will be placed into one of two groups by chance: one taking standard LT4 alone, and the other taking both LT4 and LT3. Researchers will monitor blood tests, cholesterol levels, and everyday well-being over six months to see which treatment gives better control and quality of life.

At a glance

Status
Authorised
Phase
Therapeutic use (Phase IV)
Sponsor
Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.
Enrolment target
110
Start
26 Jun 2026

What is this study about?

The thyroid is a small gland in the neck that produces hormones essential for energy, metabolism, and overall health. When someone has their thyroid removed due to cancer, their body can no longer make these hormones. They must take daily replacement medicines for the rest of their lives. The standard treatment is levothyroxine (LT4), which the body usually converts into the active hormone, liothyronine (LT3).

Some people with advanced thyroid cancer take targeted cancer medicines known as tyrosine kinase inhibitors (TKIs). While these drugs help control the cancer, they often interfere with how the body handles thyroid hormones. This can make thyroid levels swing too high or too low, requiring frequent blood tests and dose changes to stay on track.

This study aims to find out if giving both hormones (LT4 and LT3) together provides smoother, more reliable control than LT4 alone in patients taking TKIs. Researchers want to see if the combination keeps hormone levels within the target range without needing constant dose adjustments.

By comparing the two approaches, doctors hope to learn whether combination therapy can improve daily quality of life, keep cholesterol levels healthier, and make cancer care simpler and more comfortable for patients.

Key takeaways

  • Tests whether taking two thyroid hormones (LT4 and LT3) is better than LT4 alone.
  • Aimed at adults with advanced thyroid cancer who take targeted cancer drugs (TKIs).
  • Lasts around 24 weeks with clinic check-ups and regular blood tests.
  • Aims to keep hormone levels stable without needing frequent dose changes.
  • Participation is voluntary and does not stop your regular cancer treatment.

Who may be eligible?

This study is open to adults aged 18 and older who have advanced thyroid cancer and have previously had surgery to remove their thyroid gland.

To be considered, you must also be starting or currently receiving treatment with a targeted cancer medicine known as a tyrosine kinase inhibitor (TKI). Because your thyroid gland has been removed, you must already be taking daily thyroid hormone replacement.

Your hospital care team will check your full medical history, current medications, and general health to confirm whether this study is safe and suitable for your specific situation.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

  1. I am aged 18 or over.
  2. I have had surgery to remove my thyroid gland.
  3. I have advanced thyroid cancer.
  4. I am taking or about to start a targeted medicine called a tyrosine kinase inhibitor (TKI).
  5. I am currently taking daily thyroid hormone replacement.
Answer every question to see your result.

What does participation involve?

Taking part in this study lasts for about 24 weeks (roughly six months). If you join, you will be assigned by chance to receive either standard LT4 therapy or the combination of LT4 and LT3. The study medicines are taken by mouth as tablets or oral liquid drops.

You will visit the clinic at regular points, typically at the start, and then at weeks 4, 12, and 24. During these visits, the study team will take routine blood samples to check your thyroid hormone levels (TSH, FT3, FT4) and cholesterol. They may also test a small sample of your DNA to see if certain genes affect how you process thyroid hormones.

You will also be asked to fill in simple questionnaires about how you feel and how your treatment affects your day-to-day life. Your doctor will monitor your health closely throughout to ensure your hormone levels stay safe.

Potential risks and benefits

You might benefit from closer monitoring of your thyroid levels, and the combination treatment could potentially help keep your hormones steadier and improve how you feel. However, there is no guarantee of direct personal benefit. The main risks involve your thyroid hormone levels becoming slightly too high or too low, which can cause symptoms such as tiredness, feeling unusually hot or cold, or a fast heartbeat. Your medical team will monitor you carefully with regular blood tests to minimise these risks. Taking part is entirely voluntary, and you are free to leave the study at any time without your regular cancer care being affected.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.
  • —
    Unverified
    Italy

Common questions

What is the difference between LT4 and LT3?

LT4 (levothyroxine) is the standard replacement hormone that the body slowly converts into LT3 (liothyronine), which is the active hormone used directly by your cells. This study is testing whether taking both together works better than taking LT4 alone.

Will this trial change my main cancer treatment?

No. You will continue to take your prescribed cancer medicine (the tyrosine kinase inhibitor). This study only tests the hormone replacement medicines you take alongside it.

Can I choose which treatment group I am in?

No. A computer places participants into groups at random. This gives both groups a fair comparison and ensures the study results are reliable.

How often will I need blood tests?

Blood tests are usually taken before starting, and then at weeks 4, 12, and 24, to check your hormone and cholesterol levels.

What happens if my hormone levels become unbalanced?

Your study doctors will check your results regularly. If your thyroid levels move outside the safe target range, your doctor can adjust your medication to protect your health.

How to find out more

Always speak to your GP or specialist before deciding to take part in a study.

Discussion

Community discussion

Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.